WHO suggestions need manufacturers to carry out a constant risk administration process for sterility test isolators, such as normal possibility assessments and the development of possibility-primarily based control tactics. Manufacturers aiming to put into action these procedures should deliver sturdy validation information to reveal their equivalence to pharmacopoeial strategies. waiting for link from Forum Profiles (11)